Given the data presented here, we conclude that finding TMEM16A activators, that is, stimulators of the channel activity acting specifically in non-proliferating differentiated cells, remains a bona fide goal for drug discovery in CF and likely other chronic obstructive airway diseases. This evidence concerns the gene ANO1 and cystic fibrosis.